Brief: Ose Immunotherapeutics Reports Full Year Financial Results

Ose Immunotherapeutics SA

27/04/2023 17:37

April 27 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS REPORTS FULL YEAR 2022 FINANCIAL
RESULTS
AND PROVIDES BUSINESS STRATEGY UPDATE
    * 2022 TOTAL TURNOVER OF EUR 18 MILLION DRIVEN BY STRATEGIC
PARTNERSHIPS WITH PHARMACEUTICAL COMPANIES
    * EUR 25.6 MILLION AVAILABLE CASH AS OF DECEMBER 31(ST) 2022
    * REINFORCED FINANCIAL VISIBILITY UNTIL Q2 2024 SUPPORTED BY
A
RECENT BRIDGE FINANCING (DETAILED BELOW: "ADDITIVE FINANCING
SECURED IN 2023").
    * * REINFORCED FINANCIAL VISIBILITY UNTIL Q2 2024 SUPPORTED
BY A
RECENT BRIDGE FINANCING
    * 2022 COMPANY RECORDED A CONSOLIDATED OPERATING LOSS OF EUR
-18
MILLION
    * OSE IMMUNOTHERAPEUTICS HAS SIGNED ON 27 APRIL 2023, AN
EQUITY
FINANCING LINE WITH VESTER FINANCE1.
    * VESTER FINANCE HAS UNDERTAKEN TO SUBSCRIBE TO A MAXIMUM OF
2,800,000 SHARES OF COMPANY, REPRESENTING A MAXIMUM OF 14.8% OF
SHARE CAPITAL, ON ITS OWN INITIATIVE, OVER A MAXIMUM PERIOD OF
24 MONTHS
    * SHARES WILL BE ISSUED ON BASIS OF AN AVERAGE STOCK MARKET
PRICE
PRECEDING EACH ISSUE2, REDUCED BY A MAXIMUM DISCOUNT OF 6%

Source text for Eikon:  ID:nBw33d37Ja 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))